Lexaria BioScience (NASDAQ: LEXX- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive to bring news the company is now trading on the Nasdaq capital markets. That includes an offering with gross proceeds of 9.6 million.
Bunka telling Proactive what has gotten the company to this point and why the move was made, He also talked about what he feels will be a big 2021 for Lexaria.